Sabra Mazin's most recent trade in ClearPoint Neuro Inc was a trade of 386 Common Stock done at an average price of $9.6 . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 9.57 per share. | 31 Dec 2025 | 386 | 44,470 (0%) | 0% | 9.6 | 3,694 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.11 per share. | 10 Oct 2025 | 7,480 | 44,084 (0%) | 0% | 26.1 | 195,303 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 10.15 per share. | 30 Jun 2025 | 361 | 51,564 (0%) | 0% | 10.1 | 3,664 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 13,050 | 52,202 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 13,050 | 57,830 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.18 per share. | 12 Mar 2025 | 6,627 | 51,203 (0%) | 0% | 13.2 | 87,344 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,827 | 51,802 (0%) | 0% | - | Common Stock | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,827 | 13,827 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.19 per share. | 06 Mar 2025 | 7,022 | 44,780 (0%) | 0% | 13.2 | 92,620 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 33,210 | 33,210 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 4.53 per share. | 31 Dec 2024 | 784 | 37,975 (0%) | 0% | 4.5 | 3,552 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.39 per share. | 10 Oct 2024 | 7,465 | 37,191 (0%) | 0% | 11.4 | 85,026 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 4.58 per share. | 28 Jun 2024 | 767 | 44,656 (0%) | 0% | 4.6 | 3,513 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 65,252 | 65,252 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 6,913 | 27,654 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 6,913 | 47,352 (0%) | 0% | 0 | Common Stock | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.24 per share. | 06 Mar 2024 | 3,463 | 43,889 (0%) | 0% | 6.2 | 21,609 | Common Stock |
| ClearPoint Neuro Inc | Sabra Mazin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 5.77 per share. | 29 Dec 2023 | 590 | 40,439 (0%) | 0% | 5.8 | 3,404 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 6.15 per share. | 30 Jun 2023 | 552 | 47,452 (0%) | 0% | 6.2 | 3,395 | Common Stock |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 34,567 | 34,567 | - | - | Restricted Stock Units | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 11,522 | 11,522 | - | - | Stock Options (right to buy) | |
| ClearPoint Neuro Inc | Mazin Sabra | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 46,000 | 46,900 (0%) | 0% | 0 | Common Stock |